In silico evaluation and exploration of antibiotic tuberculosis treatment regimens.
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Journal:BMC systems biology, Volume: 9
Improvement in tuberculosis treatment regimens requires selection of antibiotics and dosing schedules from a large design space of possibilities. Incomplete knowledge of antibiotic and host immune dynamics in tuberculosis granulomas impacts clinical trial design and success, and variations among clinical trials hamper side-by-side comparison of regimens. Our objective is to systematically evaluate the efficacy of isoniazid and rifampin regimens, and identify modifications to these antibiotics that improve treatment outcomes.